Abstract
Less than a decade ago, metastatic castration-resistant prostate cancer (mCRPC) was deemed to be a "chemoresistant" disease, with a poor prognosis. The landmark TAX327 trial, published in 2004, showed that a course of chemotherapy based on the taxane docetaxel could extend survival for men with mCRPC. Then, in 2010 it was reported that men with mCRPC who progressed during or after docetaxel could gain a further survival benefit from a second line of chemotherapy, based on another taxane, cabazitaxel.
Cite
CITATION STYLE
Bavbek, S. (2017). Chemotherapy in the management of prostate cancer. In Principles and Practice of Urooncology: Radiotherapy, Surgery and Systemic Therapy (pp. 351–365). Springer International Publishing. https://doi.org/10.1007/978-3-319-56114-1_21
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
